Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence
ConclusionWhen using real-world evidence, sunitinib is found to be a cost-effective treatment compared to pazopanib in mRCC patients in Canada.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology